ABLYNX overview

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

Primary objective of safety and tolerability met In the three highest dose groups, 100% of patients achieved a 75% or greater reduction in disease activity compared to 0% for placebo The onset of clinical effect was rapid and sustained throughout the study GHENT, Belgium, 26 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its partner, Merck KGaA (Darmstadt, Germany), has reported encouraging results from a study in psoriasis patients with the bi-specific...

REGULATED INFORMATION GHENT, Belgium, 18 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 154,342 common shares have been issued by the Company in exchange for €1,011,939.05 as the result of the exercise of warrants. As a result of this transaction, Ablynx now has 61,076,074 shares outstanding. The total number of rights (warrants) to subscribe to not...

ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections ALX-0171 was safe and well tolerated in a Phase IIa study in hospitalised infants with a RSV infection ALX-0171 had an immediate and significant impact on viral replication and an encouraging initial therapeutic effect in a Phase IIa study in hospitalised infants with a RSV infection [1] GHENT, Belgium, 11 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has dosed the...

REGULATED INFORMATION Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC. FMR LLC (taking into account the holdings of its subsidiary undertakings) currently holds a total of 5,571,055 Ablynx shares, representing...

REGULATED INFORMATION Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC. FMR LLC (taking into account the holdings of its subsidiary undertakings) currently holds a total of 5,581,055 Ablynx shares, representing...

REGULATED INFORMATION GHENT, Belgium, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC. FMR LLC has notified Ablynx that the shareholding in Ablynx held through financial...

GHENT, Belgium, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its CEO, Dr Edwin Moses, will present a company update at the Annual Jefferies Healthcare Conference in London on Wednesday, 16 November 2016 at 12:40 p.m. GMT (01:40 p.m. CET). The presentation will be webcast live and can be accessed on the day via this link . A replay of the webcast will be available on the Company's website, under the news & events section, for 90 days...